In this scenario, DNA-based biomarkers, including KRAS and GNAS noted to be elevated in mucin-producing cysts, and supervised machine learning techniques might represent an innovative tool to develop a comprehensive test, CompCyst, based on selected clinical and imaging features combined with cyst fluid genetic and biochemical markers, to guide the management of pancreatic cysts. This evidence concerns the gene KRAS and cyst.